The Suzhong Pharma and China Construction Bank-backed cancer drug developer is gearing up for an initial public offering after securing a new capital injection.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

SoftBank Investment Advisers contributed to a round for the cancer and immune disorder drug developer co-led by Logos Capital and Boxer Capital.

Strategic partner Thermo Fisher Scientific was among the participants in a series B round for the diagnostics technology producer.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Azeria Therapeutics has wound down voluntarily four years after being set up to advance University of Cambridge and Cancer Research UK work.

Boreal Ventures will invest in deep tech companies emerging from ÉTS Montréal’s incubator Centech and the wider Quebec ecosystem.

Legend Capital has returned to invest in the metabolic and immunological disease-focused biotechnology developer, having backed its series A round two years ago.

MIT’s cancer and infectious disease therapy spinout has added $40m to a round that will support the progression of its lead asset into the clinic.

Xfund is among the backers of a $17m round for ImmuneID, which has been set up to commercialise research from Harvard University and Johns Hopkins University.